Your browser doesn't support javascript.
loading
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Zhang, Tian; Harrison, Michael R; O'Donnell, Peter H; Alva, Ajjai S; Hahn, Noah M; Appleman, Leonard J; Cetnar, Jeremy; Burke, John M; Fleming, Mark T; Milowsky, Matthew I; Mortazavi, Amir; Shore, Neal; Sonpavde, Guru P; Schmidt, Emmett V; Bitman, Bojena; Munugalavadla, Veerendra; Izumi, Raquel; Patel, Priti; Staats, Janet; Chan, Cliburn; Weinhold, Kent J; George, Daniel J.
Afiliação
  • Zhang T; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Harrison MR; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • O'Donnell PH; University of Chicago, Chicago, Illinois.
  • Alva AS; University of Michigan Medical Center, Ann Arbor, Michigan.
  • Hahn NM; Johns Hopkins University, Baltimore, Maryland.
  • Appleman LJ; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Cetnar J; Oregon Health and Science University Center for Health, Portland, Oregon.
  • Burke JM; Rocky Mountain Cancer Centers, Aurora, Colorado.
  • Fleming MT; Virginia Oncology Associates, Norfolk, Virginia.
  • Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
  • Mortazavi A; Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina.
  • Sonpavde GP; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Schmidt EV; Merck & Co, Inc, North Wales, Pennsylvania.
  • Bitman B; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
  • Munugalavadla V; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
  • Izumi R; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
  • Patel P; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
  • Staats J; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
  • Chan C; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
  • Weinhold KJ; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
  • George DJ; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Cancer ; 126(20): 4485-4497, 2020 10 15.
Article em En | MEDLINE | ID: mdl-32757302
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Urológicas / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Urológicas / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article